MT2A is highly expressed in hypoxic tumor tissues compared to normoxic ones in breast cancer patients, among whom higher expression of MT2A is associated with a worse prognosis, and it is required for breast tumor growth. This evidence concerns the gene MT2A and breast carcinoma.